ALX Oncology Holdings Total Assets 2019-2021 | ALXO

ALX Oncology Holdings total assets from 2019 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
ALX Oncology Holdings Annual Total Assets
(Millions of US $)
2020 $436
2019 $11
2018 $0
ALX Oncology Holdings Quarterly Total Assets
(Millions of US $)
2021-09-30 $400
2021-06-30 $421
2021-03-31 $433
2020-12-31 $436
2020-09-30 $262
2020-06-30 $103
2020-03-31 $0
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
2018-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.749B $0.001B
ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69